This site is intended for healthcare professionals
Molecular diagnostics for RET inhibition in NSCLC and thyroid cancers

RET inhibitors

Read time: 75 mins
Last updated:10th Sep 2021
Published:10th Sep 2021

Discover how aberrant rearranged during transfection (RET) tyrosine kinase signalling drives thyroid cancer and non-small cell lung cancer (NSCLC). 

  • Understand RET kinase physiology and the mode of action (MOA) of RET inhibitors
  • Find out how RET mutations can be targeted effectively to manage NSCLC and thyroidcancer
  • Explore the clinical evidence for RET inhibitors
  • Understand mechanisms of RET inhibitor resistance

RET inhibitor mode of action

Recent developments in our understanding of the key oncogenic drivers of various types of cancers has facilitated a transition in oncology, from a ‘one size fits all’ approach to precision medicine, whereby treatment is directed by the patient’s individual molecular profile1.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

RET inhibition in non-small cell lung cancer

Dr Alexander Drilon outlines the evidence which led to the regulatory approvals of rearranged during transfection (RET) inhibitors for RET fusion-positive non-small cell lung cancers (NSCLC).

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

RET inhibition in thyroid cancer

Dr Lori Wirth, an international authority in advanced thyroid cancer and head and neck oncology, discusses the importance of molecular testing for the application of rearranged during transfection (RET) inhibitors in the clinic.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

RET inhibitor safety

In the following video Dr Alexander Drilon discusses the main side effects of rearranged during transfection (RET) inhibitors to be aware of, noting the differences between the adverse event profiles of the approved first-generation selective RET inhibitors in non-small cell lung cancer (NSCLC).

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Ongoing clinical trials for RET inhibitors

In the following video Dr Lori Wirth provides an overview of ongoing clinical trials for rearranged during transfection (RET) inhibitors in the treatment and management of medullary thyroid cancer (MTC).

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

RET inhibitor resistance mechanisms

Patients with RET-driven cancers may be resistant to certain tyrosine kinase inhibitors due to either intrinsic or acquired mechanisms5,10.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

References

  1. Malone E, Oliva M, Sabatini P, Stockley T, Siu L. Molecular profiling for precision cancer therapies. Genome medicine. 2020;12(1). doi:10.1186/S13073-019-0703-1.
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Welcome: